Pfizer Consolidated Operational Revenue Growth Excluding by Quarter

Pfizer Consolidated Operational Revenue Growth Excluding: 5.0% in Q2 2026.

“Second-quarter 2026 revenues totaled $15.0 billion, an increase of $381 million, or 3%, compared to the prior-year quarter, reflecting an operational increase of $164 million, or 1%, and a favorable impact of foreign exchange of $217 million. The operational increase was driven by an increase in revenues for Eliquis, Padcev, the Vyndaqel family, Lorbrena and several other products across categories, partially offset by a decline in COVID-19 product revenues and several other products across categories. Excluding contributions from Comirnaty and Paxlovid, revenues for the second quarter grew 5% operationally. Additionally, second-quarter revenues of our Launched and Acquired Products (1) grew 18% operationally.”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Pfizer guides and evaluates core commercial performance on an operational (constant-currency) basis excluding COVID-19 products.

• Pfizer Biopharma Revenues Excluding Comirnaty & Paxlovid ($M)–
• Foreign Exchange (FX) Impact on Consolidated Revenues YoY ($M)217 · Q2 2026

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.